Japan ticks Gropep mix

By Staff Writers
Thursday, 21 April, 2005

Adelaide biopharma GroPep has announced that a Japanese biopharmaceutical company has received regulatory approval in Japan to manufacture a biopharmaceutical product containing one of GroPep's products.

GroPep said commercial secrecy prevented it naming the ingredient, the company, or the product, but it is the sixth biopharmaceutical product containing GroPep's proprietary cell-culture products to receive regulatory approval.

It's not going to be a big source of revenue, but GroPep said the Japanese product is currently undergoing clinical trials for several other indications, some of which have multi-billion global markets.

CEO Bob Finder said the Japanese approval reinforced growing international recognition of the superiority of GroPep's cell culture products for the manufacture of certain biopharmaceutical products.

Related News

The cause of 2022's mpox outbreak revealed

Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...

New gene therapy treats liver disorder in growing children

Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...

High folic acid in pregnancy could cause early bleeding

Women taking at least 800 micrograms of folic acid daily were more likely to report spotting and...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd